Kendall Capital Partners — 2016 Investments

3 investments dated 2016 · listed companies and verified rows first · show all

eGenesisegenesis.comAug 2016SEC filingmedium confidence

Biotechnology company using multiplex gene editing to develop genetically engineered porcine organs for human transplantation.

BiotechBrookline, US

Luhan Yang(President, Secretary and Treasurer)Geoff MacKay(Chief Executive Officer)

Board seatGeorge M. Church· per SEC Form D · $3M raise · filed Aug 2016

Co-investorsAlta Partners ARCH Venture Partners Catalio Capital Management, LP HBM Healthcare Investments HBM Partners Khosla Ventures +12 more

Tarveda Therapeutics inJan 2016SEC filingmedium confidence

BiotechWatertown, US

Omid Farokhzad(Director)inRobert S. Langer, Jr.(Director)Robert S. Langer(Director)Andrew J. Fromkin(Executive Officer, Director)Leila Alland(Executive Officer)inRichard Wooster(Executive Officer)in

Board seatRobert Langer· per SEC Form D · $38M raise · filed Feb 2017

Co-investors+ND Capital New Enterprise Associates (NEA)

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Lyndra

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.